Clinical Trial Update: Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial update for TL-895 with navtemadlin in treatment-naïve and relapsed/refractory B cell malignancies, including CLL/SLL and related lymphomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Navtemadlin (navtemadlin)
• TL-895

Snippet

Sponsor: Telios Pharma, Inc. | Conditions: Relapsed/Refractory B Cell Malignancies, Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN